AMG208 AMG-208 is a small molecule inhibitor of the focal adhesion kinase (FAK) protein. It is currently being studied as a potential cancer therapy, particularly in the treatment of solid tumors such as breast cancer, ovarian cancer, and pancreatic cancer. AMG208 AMG-208 was first developed by Amgen Inc. and has undergone several clinical trials.
The chemical name of AMG208 AMG-208 is 2-(4-methyl-5-(2-(phenylamino)pyrimidin-4-ylamino)thiazol-2-ylamino)acetic acid.
The molecular formula of AMG208 AMG-208 is C18H16N6O2S.
The formula weight of AMG208 AMG-208 is 384.42 g/mol.
The CAS number of AMG208 AMG-208 is 1002304-34-8.
Top Ten Keywords from Google and Synonyms
Synonyms: AMG 208, AMG-208, AMG208, 2-(4-Methyl-5-(2-phenylamino-4-pyrimidinyl)thiazol-2-ylamino)acetic Acid
Health Benefits of AMG208 AMG-208
AMG208 AMG-208 has shown promising results in preclinical studies for the treatment of various types of cancers, particularly those that are difficult to treat with current therapies. By inhibiting FAK, a protein that plays a key role in regulating cell growth and survival, AMG208 AMG-208 works to slow or stop the growth of cancer cells.
Clinical studies have shown that AMG208 AMG-208 can effectively treat solid tumors, including breast cancer, ovarian cancer, and pancreatic cancer. In one phase I study, researchers found that AMG208 AMG-208 was well-tolerated and showed signs of efficacy in patients with advanced solid tumors.
AMG208 AMG-208 works by specifically targeting FAK, a protein that is often overexpressed in cancer cells, leading to increased cell growth and spread. By blocking FAK, AMG208 AMG-208 inhibits the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression.
AMG208 AMG-208 has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include fatigue, nausea, vomiting, diarrhea, and decreased appetite. More severe side effects may occur in some patients, such as high blood pressure, bleeding, or liver damage. Patients should be closely monitored for any adverse reactions while taking AMG208 AMG-208.
The most common side effects of AMG208 AMG-208 include:
More severe side effects may occur in some patients, such as:
The dosing of AMG208 AMG-208 depends on the type of cancer being treated and other individual factors. It is typically administered orally in capsule form, either alone or in combination with other chemotherapy drugs. The recommended dose varies depending on the clinical trial or physician's discretion.
In conclusion, AMG208 AMG-208 is a promising drug candidate for cancer therapy, particularly in the treatment of solid tumors. As an inhibitor of FAK, it shows potential in slowing or stopping cancer progression in tumors that overexpress this protein. While further clinical trials are needed to determine its efficacy and safety, AMG208 AMG-208 represents an important step towards precision medicine and molecular targeted therapy in cancer treatment.